[
  {
    "ts": null,
    "headline": "AstraZeneca Plans to Invest $50 Billion in U.S. by 2030",
    "summary": "The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.",
    "url": "https://finnhub.io/api/news?id=a8377b6e678d01e35e6ddf910f5f800990e05af8561ac3910b927e75feba7bee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753138620,
      "headline": "AstraZeneca Plans to Invest $50 Billion in U.S. by 2030",
      "id": 136031227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.",
      "url": "https://finnhub.io/api/news?id=a8377b6e678d01e35e6ddf910f5f800990e05af8561ac3910b927e75feba7bee"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade",
    "summary": "Eli Lilly (LLY) closed at $762.18 in the latest trading session, marking a -1.23% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=ee3edd34fac28227bae7c93b34eb0c996f16b7c7909b48c6e9d132cdedf0e638",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753134303,
      "headline": "Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade",
      "id": 136031228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) closed at $762.18 in the latest trading session, marking a -1.23% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=ee3edd34fac28227bae7c93b34eb0c996f16b7c7909b48c6e9d132cdedf0e638"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca announces $50 billion US manufacturing investment, matching its big pharma peers",
    "summary": "AstraZeneca announces largest ever investment in U.S. manufacturing",
    "url": "https://finnhub.io/api/news?id=655208f1672cea4d00a5215ad51b6c505853d35d1972d8711b057becac987943",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753133401,
      "headline": "AstraZeneca announces $50 billion US manufacturing investment, matching its big pharma peers",
      "id": 136031229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AstraZeneca announces largest ever investment in U.S. manufacturing",
      "url": "https://finnhub.io/api/news?id=655208f1672cea4d00a5215ad51b6c505853d35d1972d8711b057becac987943"
    }
  },
  {
    "ts": null,
    "headline": "Model Portfolio For Capital Appreciation, July 2025",
    "summary": "Build a high-performing portfolio with over 20 expert-recommended stocks. Focused on capital growth, beat the S&P 500 using institutional-grade picks. See more.",
    "url": "https://finnhub.io/api/news?id=e1c798100ae494d89b0ad8561f66cf75a2e7da04aa6e2ba800c19a315d605d20",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753133004,
      "headline": "Model Portfolio For Capital Appreciation, July 2025",
      "id": 136028779,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/482730527/image_482730527.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Build a high-performing portfolio with over 20 expert-recommended stocks. Focused on capital growth, beat the S&P 500 using institutional-grade picks. See more.",
      "url": "https://finnhub.io/api/news?id=e1c798100ae494d89b0ad8561f66cf75a2e7da04aa6e2ba800c19a315d605d20"
    }
  },
  {
    "ts": null,
    "headline": "Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.",
    "summary": "A Goldman ranking of S&P 500 sectors by price/earnings ratios reveals opportunities in healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=cd17fd1452b4268272a9f25932e02fa3a251bf4ddd1b877b3cdb8c32293636a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753116000,
      "headline": "Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.",
      "id": 136031230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A Goldman ranking of S&P 500 sectors by price/earnings ratios reveals opportunities in healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=cd17fd1452b4268272a9f25932e02fa3a251bf4ddd1b877b3cdb8c32293636a7"
    }
  },
  {
    "ts": null,
    "headline": "GE HealthCare Stock: Hidden Winner Of Alzheimer's Drug Boom",
    "summary": "GE HealthCare Technologies' market position, rising earnings, and improving financials make it an attractive investment opportunity. Read more on GEHC stock.",
    "url": "https://finnhub.io/api/news?id=9b754ef528fe7b96b0cce9ccb833959abb45dd40ecee9b9f814293e42b25b101",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753106894,
      "headline": "GE HealthCare Stock: Hidden Winner Of Alzheimer's Drug Boom",
      "id": 136027327,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/82190263/image_82190263.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "GE HealthCare Technologies' market position, rising earnings, and improving financials make it an attractive investment opportunity. Read more on GEHC stock.",
      "url": "https://finnhub.io/api/news?id=9b754ef528fe7b96b0cce9ccb833959abb45dd40ecee9b9f814293e42b25b101"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in This Under-the-Radar Weight Loss Stock?",
    "summary": "Rhythm Pharmaceuticals' lone approved product currently generates minimal sales.  If you're interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=f85d4a2777a5e9e4bec908ccaf1f50d5025018ce80c03d508429d8c2aa8de09e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753105500,
      "headline": "Should You Invest in This Under-the-Radar Weight Loss Stock?",
      "id": 136025388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Rhythm Pharmaceuticals' lone approved product currently generates minimal sales.  If you're interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=f85d4a2777a5e9e4bec908ccaf1f50d5025018ce80c03d508429d8c2aa8de09e"
    }
  },
  {
    "ts": null,
    "headline": "Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025",
    "summary": "J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.",
    "url": "https://finnhub.io/api/news?id=b68b0e8b783d65219841418cceddcf5f3bd8e35ed1c4cc6bf5878cb8d8027ef6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753105260,
      "headline": "Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025",
      "id": 136025389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.",
      "url": "https://finnhub.io/api/news?id=b68b0e8b783d65219841418cceddcf5f3bd8e35ed1c4cc6bf5878cb8d8027ef6"
    }
  },
  {
    "ts": null,
    "headline": "Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm",
    "summary": "Biogen joins major drugmakers such as Eli  Lilly, Roche and Merck, who have all announced investments in the U.S. as the industry braces for potential import levies.  Drugs have so far been exempt from Trump's reciprocal tariffs, but he has often argued that separate levies are needed to bolster domestic manufacturing and avoid relying on other countries for medicine supply.  Earlier this month, Trump said the tariffs may be delayed, but could be as high as 200%.",
    "url": "https://finnhub.io/api/news?id=938367485f95d02b2dad4104e740a99fbe075f769bb7c30dcf9509fb11612434",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753098092,
      "headline": "Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm",
      "id": 136025390,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Biogen joins major drugmakers such as Eli  Lilly, Roche and Merck, who have all announced investments in the U.S. as the industry braces for potential import levies.  Drugs have so far been exempt from Trump's reciprocal tariffs, but he has often argued that separate levies are needed to bolster domestic manufacturing and avoid relying on other countries for medicine supply.  Earlier this month, Trump said the tariffs may be delayed, but could be as high as 200%.",
      "url": "https://finnhub.io/api/news?id=938367485f95d02b2dad4104e740a99fbe075f769bb7c30dcf9509fb11612434"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Competition Melts Away",
    "summary": "Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.",
    "url": "https://finnhub.io/api/news?id=309600c6e7f1364dec625a415f7b6ae30fc3d7ed41de0faac8e568f7271fe5e9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753092000,
      "headline": "Eli Lilly: Competition Melts Away",
      "id": 136024949,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418928072/image_1418928072.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.",
      "url": "https://finnhub.io/api/news?id=309600c6e7f1364dec625a415f7b6ae30fc3d7ed41de0faac8e568f7271fe5e9"
    }
  }
]